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Background: Organized screening based on Pap tests has substantially reduced deaths from cervical cancer in
many countries, including Australia. However, the impact of the program depends upon the degree to which
women participate. A new method of screening, testing for human papillomavirus (HPV) DNA to detect the virus
that causes cervical cancer, has recently become available. Because women can collect their own samples for this
test at home, it has the potential to overcome some of the barriers to Pap tests. The iPap trial will evaluate whether
mailing an HPV self-sampling kit increases participation by never- and under-screened women within a cervical
screening program.
Methods/Design: The iPap trial is a parallel randomized controlled, open label, trial. Participants will be Victorian
women age 30–69 years, for whom there is either no record on the Victorian Cervical Cytology Registry (VCCR) of a
Pap test (never-screened) or the last recorded Pap test was between five to fifteen years ago (under-screened).
Enrolment information from the Victorian Electoral Commission will be linked to the VCCR to determine the
never-screened women. Variables that will be used for record linkage include full name, address and date of birth.
Never- and under-screened women will be randomly allocated to either receive an invitation letter with an HPV
self-sampling kit or a reminder letter to attend for a Pap test, which is standard practice for women overdue for a
test in Victoria. All resources have been focus group tested. The primary outcome will be the proportion of women
who participate, by returning an HPV self-sampling kit for women in the self-sampling arm, and notification of a
Pap test result to the Registry for women in the Pap test arm at 3 and 6 months after mailout. The most important
secondary outcome is the proportion of test-positive women who undergo further investigations at 6 and
12 months after mailout of results.
Discussion: The iPap trial will provide strong evidence about whether HPV self-sampling could be used in Australia
to improve participation in cervical screening for never-and under-screened women.
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Keywords: HPV DNA testing, Home-based, Self-sample, Cervical screening, Participation* Correspondence: dgertig@vcs.org.au
7Victorian Cervical Cytology Registry, PO Box 161, Carlton South, Vic 3053,
Australia
Full list of author information is available at the end of the article
© 2014 Sultana et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Sultana et al. BMC Cancer 2014, 14:207 Page 2 of 11
http://www.biomedcentral.com/1471-2407/14/207Background
Organized screening programs based on Pap tests have
substantially reduced deaths from cervical cancer in re-
source rich settings [1], including Australia [2]. However,
some women are missing out on the benefit because they
do not have regular Pap tests [3]. About half (54%) of
women diagnosed with invasive or micro-invasive cervical
cancer in Victoria, Australia, have no known screening
history and a further 25% were last screened more than
2.5 years before diagnosis [4]. Inclusion of these women
into screening programs is crucial to further reducing
cervical cancer incidence and mortality.
Numerous strategies have been used to improve partici-
pation in cervical screening, but most have had limited
success, particularly in engaging ‘hard to reach’ groups.
Common barriers include test-related issues such as pain,
discomfort or embarrassment, or doctor-related issues
including access, difficulty obtaining appointments or time
constraints [5-9]. Reminder letters have been shown to be
one of the most effective strategies at prompting women to
re-attend [10]. In Victoria, a reminder letter is sent once a
woman has not attended by 27 months since her last nega-
tive Pap test and another reminder is sent at 36 months if
she has not responded to the first reminder. About 40%
women had a subsequent Pap smear within three months of
receiving the first reminder letter [4]. To increase participa-
tion in Victoria, a pilot study of 10,000 second reminder let-
ters to women who did not respond to the first reminder
was conducted in June 2011. Whilst the intervention was
effective, the response rate decreased with increasing time
since the last Pap test, ranging from 10% for women
whose last Pap test was six years ago to 0.4% for women
whose last Pap test was more than fifteen years ago [11].
Testing for DNA of the human papillomavirus (HPV),
the virus that causes cervical cancer, has been evaluated
as a primary screening test over the last decade [12-15].
Evidence from randomized trials suggests that HPV testing
is more sensitive than Pap testing and has a better negative
predictive value [16,17]. Furthermore, unlike a Pap test,
women can collect their own samples for HPV testing.
Self-collected samples have better sensitivity than Pap
test and comparable sensitivity to those obtained by
physicians [18-21].
Rationale
Eight randomised controlled trials of HPV self-sampling
evaluating whether it improves participation in screening
have been reported from countries with organised screening
programs (Table 1) [22-29]. The studies were restricted
to non-attendees, although the eligibility criteria varied.
Non-attendees in these studies referred to women who did
not respond to an initial invitation or a 6 months reminder
letter and who were overdue between three months and six
years or more. All studies compared invitations to performHPV self-sampling with invitations to attend for Pap tests,
with HPV self-sampling kits mailed to women and returned
by mail. Women in the comparison arm received a standard
invitation letter or a reminder letter to attend for a Pap test.
Six of the trials used Hybrid Capture II for their HPV DNA
test [22-27], while one study used Abbott Real Time HPV
test [29] and another study used GP5+/6+ PCR testing [28].
All trials found participation to be significantly higher
for HPV self-sampling than for a reminder to attend for
Pap testing. However, the actual participation proportion
in both the intervention (range 10% to 39%) and the con-
trol arms (range 2% to 26%) varied widely, with an abso-
lute difference in participation between trial arms ranging
between 3% and 30%. The studies also found a high com-
pliance with follow-up regimens: between 86% and 98% of
women who tested positive to HPV DNA underwent
appropriate follow-up investigations [22,24-28] except for
the trial in France [29]. There are no published trials that
have had sufficient power to evaluate participation of
never-screened women separately to under-screened. In
summary, the trials show that mailing HPV self-sampling
kits to non-attendees increases participation compared
with standard reminder letters and that a high proportion
of women who test positive undergo appropriate follow-up
investigations. Because the participation fractions varied
widely across countries, locally conducted trials are neces-
sary to estimate the likely effect and cost effectiveness for
a given country. Thus, we are conducting a randomised
controlled trial to evaluate whether mailing an HPV self-
sampling kit will increase participation in cervical screen-
ing in Victoria, Australia, when compared with a reminder
letter to attend for a Pap test.
Primary objective
To determine whether offering home-based HPV self-
sampling increases participation in cervical screening, over-
all and separately for never- and under-screened women
when compared to current practice of a reminder letter to
attend for a Pap test.
Secondary objectives
The main secondary objective is to estimate the proportion
of women who have a positive HPV test who undergo
appropriate further investigation, separately for never-
and under-screened women. Other secondary objectives
include documenting women’s experience with home-
based HPV self-sampling, their willingness to participate




We will conduct a parallel, randomized controlled, open
label trial. Women will be randomly allocated to either the
Table 1 Review of trials comparing participation in HPV self-sampling (SS) and reminder letter to attend for a Pap test
Study Area Eligibility Intervention Comparison Device Test, HPV+ Participation Follow-up
HPV SS Pap arm
Sancho-Garnier [29] France 35-69 yrs; no Pap smear for ≥2 years;
did not respond to first invitation
HPV SS kit* Standard invitation Dacron swab Abbott real
Time, 17.6%
18.3% 2% 41%
Szarewski [25] UK 25-65 yrs; ≥6 years overdue HPV SS kit Standard invitation Cotton swab HCII, 8.3% 10.2% 4.5% 87.5%
Wikstrom [22] Sweden 39-60 yrs; ≥6 years overdue HPV SS kit* + 2nd
reminder
Standard invitation Qvintip HCII, 6% 39% 9% 98%







-Direct mail (1)* -Standard recall (3)
-On demand (2) -HPV at the clinic (4)
Virtanen [23] Finland 30-60 yrs; did not respond to
primary invitation
HPV SS kit Reminder letter Delphi Screener HCII 29.8% 26.2% -
Virtanen [24] 30-60 years; did not respond to
primary invitation
HPV SS kit* Reminder letter Delphi Screener HCII, 12.3% 32% 26% 86.6%
Gok [27] Netherlands 30-60 yrs; did not respond to
invitation or 6 month reminder
HPV SS kit* Second reminder letter* Delphi screener HCII, 10.3% 26.6% 16.4% 90.4%
Bais [28] 30-50 yrs, did not respond to
invitation or 6 month reminder
HPV SS kit Second reminder letter Viba-brush +
collection tube
GP 5+/6+ PCR, 8% 34.2% 17.6% 86%
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with a kit for home-based self-sampling or the current
practice arm of a letter prompting them to attend a health
practitioner (General Practitioner (GP) or nurse) to have
a Pap test (Figure 1). Women will be stratified by their
screening history i.e. never- or under-screened.
To determine which women have no history of a previ-
ous Pap smear on the Victorian Cervical Cytology Registry
(VCCR) and are thus presumably never-screened, we will
link the VCCR to the enrolment information on the
Victorian Electoral Commission (VEC). Registration to
vote is compulsory in Australia and use of the electoral
roll for specific public health programs, such as cancer
screening, is permitted under legislation [30]. Women
whose last recorded Pap test was between five and fifteen
years ago will be defined as under-screened and identified
using the VCCR database only. Under-screened women
will be further stratified by years since last Pap test (i.e.
5 years, 6 years, 7 years, 8 years, 9 years, and 10–14 years),
with equal numbers in each stratum. Women with a
screening history whose last contact with VCCR was
15 years ago or more will probably be difficult to con-
tact given their likelihood of having changed address. In
previous VCCR studies of reminder letters, 35% of let-
ters to women whose last Pap test was 15 years ago were
“returned to sender” [11]. Within each stratum, women
will be randomly allocated in a 7:1 randomization ratioFigure 1 RCT design overview and clinical management for both nevto the intervention (HPV self-sampling) arm and the
current practice arm respectively. The unequal allocation
ratio is to ensure there is an adequate sample size in the
HPV self-sampling arm to estimate precisely the propor-
tion of women who have a positive HPV test who undergo
appropriate further investigation.
Study setting
The trial is based at the Victorian Cytology Service Inc
(VCS). VCS hosts the VCCR, which records almost all
Pap tests in Victoria (that is all tests except when a
woman chooses not to have her records recorded on
the register), and the VCS Pathology, which is a NATA
(National Association of Testing Authorities, Australia)
accredited laboratory that reports about half of those Pap
test as well as HPV tests.
In Australia, the National Cervical Screening Program
(NCSP) currently recommends that all women aged
18–69 years, who have ever been sexually active (regardless
of HPV vaccination status), should have Pap smears every
two years if they have no symptoms or history suggest-
ive of cervical pathology [31]. The NCSP is supported
by eight jurisdictional Pap test registers, of which VCCR is
the Victorian operation. Like other registers, VCCR func-
tions by: sending reminders to women when their Pap test
is overdue, following up women with abnormal Pap test re-
sults where necessary, providing laboratories with screeninger- and under-screened women.
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providing quality assurance data to ensure the quality of
reporting by laboratories. Cervical cytology and HPV re-
sults are sent to VCCR directly from reporting labora-
tories, as permitted by Victorian legislation. Almost all
results are reported to the VCCR within one week, with
longer delays for reporting histology, although most of
the latter is reported within 3 months. The trial will
make use of these existing infrastructures, including the
VCCR follow-up processes and database (known as the
Cytology information System (CIS)), which is designed
to capture the relevant outcomes quickly and efficiently.
Eligibility
Inclusion criteria
Participants will be Victorian residents, age 30–69 years,
for whom there is either no record on the VCCR of a
Pap test (never-screened) or the last recorded Pap test
in the VCCR was between five and fifteen years ago
(under-screened). Eligibility will be restricted to women
30 years of age or older given the low specificity of HPV
DNA tests in younger women [17,32].
Exclusion criteria
Different exclusion criteria apply to women in the two
screening groups and at different stages of the participant
selection process (Figure 2). For under-screened women,
information on exclusion criteria is available prior to
randomisation. Exclusions include women whose registry
based follow up has ceased due to reported hysterec-
tomy, gynaecological cancer, or migration, or those whose
most recent Pap test showed a high-grade abnormality
(these women require a different follow up pathway).
Apart from age, no information on exclusion criteria for
never-screened women is available prior to randomisa-
tion. Based on information reported by women follow-
ing randomisation and mail-out, women will be deemed
ineligible subsequently if found to be pregnant, if they
have had a hysterectomy, if they have been recently
screened (i.e. while interstate or overseas), or if the mail
is returned.
Interventions
Women allocated to the intervention (the HPV self-
sampling) arm will be mailed an envelope containing
an invitation letter, an information brochure on HPV
and cervical cancer entitled ‘The Pap test alternative:
the HPV test and cervical cancer’, and the HPV self-
sampling kit. The kit comprises a nylon-tipped flocked
swab (Copan Italia, Brescia, Italy) for vaginal sampling
enclosed in a plastic tube within a resealable plastic
bag; an instruction sheet (both written and pictorial)
on ‘How to take a vaginal sample and how to pack and
post the sample’; a pathology information form; and apostage paid envelope to return the swab and the form.
The form will ask for the woman’s country of birth,
language spoken at home, whether she identifies as an
Aboriginal or Torres Strait Islander woman, hysterectomy
status, pregnancy status, Pap screening history, updates of
her contact details, and the date she took her sample.
Women are able to nominate a GP to receive a copy of
the results to enable appropriate referral, follow-up
and management should high-risk HPV be detected.
Two to three weeks prior to receiving the kit, women
will receive a pre-invitation letter informing them of the
upcoming HPV self-sampling kit and the fact that the
test is free, and a phone number for calling the Registry
(or VCCR) with an option for cancellation of the kit. It
will also allow women to call the Registry and update
information such as a recent Pap test, correct contact de-
tails, hysterectomy, or pregnancy to identify women not eli-
gible for the trial. A multilingual flyer included with the
pre-invitation and the invitation letter will state that infor-
mation is available on the website in the ten most common
languages and that an interpreter service is available.
All materials for use in the HPV self-sampling arm were
focus group tested. Four focus groups were conducted in
August 2013 with Victorian women who would be eligible
for the trial, separated by their screening history (never-
and under-screened) and age (30–49 and 50–69 years).
The main aim was to obtain suggestions for refining all
written materials sent with the HPV self-sampling kit with
the intent of maximising response to the trial. The overall
response to the iPap concept was very positive in the focus
groups. The details of the focus group findings will be
published elsewhere.
Women in the HPV self-sampling arm will also receive
a questionnaire a few weeks later. This will collect infor-
mation about their experience with the HPV self-sampling
(mostly psycho-social: pain, discomfort, fear, embarrass-
ment; some aspects of feasibility such as ease of use, confi-
dence doing it themselves, adequacy of instructions; and
other practical issues such as ease getting an appointment
with a GP etc.) and their willingness to participate in HPV
self-sampling screening in future. Those who did not re-
turn a completed HPV self-sampling kit will be asked to
provide reasons for not participating.
Women allocated to the current practice arm will re-
ceive either a tailored invitation letter (never-screened) or
a standard reminder letter (under-screened) to have a Pap
test, as well as a Pap test brochure entitled ‘How Pap tests
can help prevent cervical cancer, and the Pap test registry’. Also
included will be a form to collect the similar information
as for the HPV self-sampling arm, and a reply paid enve-
lope for return of the form. The requested information
will enable analysis of results by cultural background and
Indigenous status, and also identify women not currently
eligible for screening.
Figure 2 Flow of participants and timeline for women in the trial.
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All the kits received will be handled, processed and
tested by VCS Pathology using the Cobas® 4800 HPV
Test (Roche Diagnostics GmBH) according to the manu-
facturer’s instructions. The test is clinically validated and
approved by the FDA. The test specifically identifies high-
risk types HPV16 and HPV18 while concurrently detecting
12 other high-risk types (31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66 and 68) in a single pool at clinically relevant cut offs
for detecting infection. This test allows for risk stratification
and identification of women who are at the highest risk of
cervical cancer (those who are 16/18 positive) [33] who
may need more intensive follow-up. The Cobas® HPV
test also has high sensitivity, which is desirable for under-
screened women [34,35]; a Beta-globin internal control for
sample adequacy, which will reduce false-negatives; and a
lower rate of cross-reactivity with low-risk HPV types,
reducing false-positives [36]. Results are either ‘positive’
for high-risk HPV (HPV 16, HPV 18 and/or other high-risk
HPV types) or ‘negative’ for high-risk HPV or unsatisfac-
tory. An ‘unsatisfactory’ result includes specimens damaged
in transit; incorrect labelling; non return of the pathology
form; inhibition by blood or other substance; or insufficient
material to test.Clinical management
Women will be sent a letter notifying them of their
HPV result directly, with a copy to their nominated GP
(if provided) within two weeks of testing. GP correspond-
ence will detail the study, HPV result and recommended
follow-up and management. The letter to the women will
be accompanied by appropriate educational information
on the meaning of the test result and the recommended
follow-up or clinical management. Figure 1 shows the pro-
posed clinical management for women in the trial. Women
in the intervention arm who test negative for high-risk HPV
will be informed of the result and advised to have regular
Pap tests as per the current screening policy. Women
positive for high-risk types other than HPV16 or
HPV18 will be asked to visit their GP for a Pap test.
Cytology will be reported as per the Australian Modified
Bethesda System [37]. Women with abnormal Pap test re-
sults (≥ possible low-grade squamous intraepithelial lesion)
will be referred for colposcopy by their GP to a specialist of
their choice. Women whose samples test positive for high-
risk HPV16 and/or HPV18 will be directly referred for col-
poscopy. Colposcopy directed biopsies will be taken for
histological examination from the cervix if clinically indi-
cated and managed as per National Health and Medical
Table 2 Power calculations assuming different
participation fraction in the two arms of the trial
Participation Statistical power
for primary aimComparison HPV self sampling
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results will be sent to the VCCR as per usual practice,
where they are coded in a standard manner and undergo
quality assurance checking. Women with positive high-
risk HPV but negative colposcopy or cytology will be
followed up actively through their GP and advised to
undergo screening (either a repeat HPV test and/or Pap)
after a year. As future screening will be outside the timeline
of this study, we cannot offer a further HPV self-sample to
these women and hence further screening will be as is rec-
ommended by the NCSP, which is presently 2 yearly Pap
testing (this is currently under review) [38]. In case of an
unsatisfactory result, new kits will be mailed to women.
Women with high-risk HPV positive results but without
a GP will be strongly recommended to contact a GP or ar-
range referral to a gynaecologist for further follow-up.
In the case of HPV 16 and/or HPV18 positive results,
women will be contacted by the VCS Liaison Physician
to help them seek further medical advice. Follow-up of
non-compliant women with positive results will be as per
VCCR usual protocol for follow up of high grade cytology
with shorter timelines and addition of phone calls. After
6 months, Medicare (Australia’s publicly funded universal
health care system) will be contacted to supply any change
of address details held for the woman for up to 2 years.
There will be no follow-up of women who chose not to re-
spond to the kit or the reminder letter, with the exception
of a participation questionnaire sent to intervention non-
responders. Women in the current practice arm with ab-
normal Pap test results will be managed as per NHMRC
guidelines by their treating doctor or nurse. Because the
women who participate in either trial arm will be part of
the screening program, in other words their test results
will be recorded on the VCCR; they will receive future
reminders from VCCR at the appropriate time interval
depending on their screening result.
Outcomes
The primary outcome is the return of a completed HPV
self-sampling kit or the notification of a Pap test result
to the VCCR per trial arm. Women in the HPV self-
sampling arm who attend for a Pap smear instead of
self-sampling will be counted as ‘successes’. Outcomes
will be measured at 3 and 6 months after the mailout of
the kits or letters. The secondary outcome is whether
women who have a positive high-risk HPV test undergo
appropriate further investigation i.e. either have a Pap
test or colposcopy depending on the type of high-risk
HPV detected. This will be measured 6 and 12 months
after women are informed of their results.
Participant timeline
The expected study duration is 36 months. Mailout of
kits and letters will occur progressively in batches overabout 4 months beginning March 2014. Results will be
mailed out within two weeks of testing and follow-up
monitored in the next 6–12 months of the mailout of
the test positive letter. The questionnaire will be mailed
to women, with differing timelines for responders and
non-responders.
Sample size
The sample size was determined by the secondary objective
(the proportion of women who have a positive HPV test
who undergo appropriate further investigation). We will
contact 16,000 women; 8,000 women never-screened and
8,000 women under-screened. 7,000 women will receive
the HPV self-sampling kit within each screening group.
Based on an estimate of 20% participation and prevalence
of positive result for HPV test of 10%, there will be at least
140 women invited for a follow-up. With 140 women we
will obtain a 95% confidence interval of +/− 5% points
around an estimated follow-up proportion of 90%. Table 2
shows estimated power for different participation fractions
in the two arms of the trial (assuming 1000 women in the
comparison arm (n1) and 7000 in the HPV self-sampling
arm (n2)). Our assumption of the participation fraction in
the current practice arm (i.e. women who will have a Pap
test within 3 months of receiving the reminder letter) is
based on a pilot study of second reminder letters, where
the response fractions varied between 0.4%, 2% and 10%
for women whose time since last Pap test was fifteen, ten
and six years respectively [11]. The sample size adequately
accounts for ineligible women (e.g. those pregnant; history
of hysterectomy; or those recently screened and not re-
corded in the Registry) and the return to sender received
during mailout. We assumed a 30% hysterectomy rate, 10%
pregnancy rate and a 30% return to senders in addition to
20% participation and 10% non-responders. The hysterec-
tomy fraction is a conservative estimate as data from the
National Hospital Morbidity identifies rates for 30–69 years
range from 2% (in 30–34 years) to 30% (in 65–69 years) [2].
The return to sender rates estimates are likewise conserva-
tive as figures from the second reminder pilot study are 19%
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(in women whose last Pap test was 10 to 14 years ago) and
35% (in women whose last Pap test was 15 years ago) [11].Selection of participants
The electoral roll from the VEC will constitute the sam-
pling frame for never-screened women. The electoral
roll will include female Victorian electors born between
1 January 1944 and 31 December 1983, excluding silent
and overseas electors. A subset of women will be selected
by simple random sampling (using a computer generated
random number) and a check will be made against the
VCCR CIS database to find a match. Women will be
matched on name, address and date of birth and if no
match is found, they are eligible for inclusion as never-
screened women. If insufficient eligible women are found
in the first random subset, another will be selected and
the process repeated.
Under-screened women will be identified directly from
the VCCR CIS database after excluding women whose last
Pap test was <5 years and ≥15 years ago, age <30 years or
70+ years, who have a prior history of cancer, hysterectomy,
are deceased, or whose follow-up has ceased. A subset of
women will then be selected by simple random sampling
(using a computer generated random number) and further
considered for: completeness of mailing address, or a
change of address, most recent Pap test showing no
high-grade abnormality and having not recently mi-
grated or moved. The two-stage process is necessary
because the second stage requires assessing episode
level information. At this point, if all the above criteria
are met, selected under-screened women are consid-
ered eligible. Under-screened women will then be
grouped into strata (5 years, 6 years, 7 years, 8 years,
9 years, and 10–14 years since last Pap) with approxi-
mately equal numbers in each stratum.Randomisation
Selected women will be randomly allocated to the two arms
of the trial in a 7:1 (HPV self-sampling: current practice) ra-
tio as per a computer generated randomisation schedule
stratified by screening history and time since last Pap test
(for under-screened only) within blocks or batches of fixed
size. The batches will ensure a close balance of numbers in
each arm at any time during the trial and will enable us to
regulate the administrative work flow as well as the work
flow in the laboratory. This will also enable us to monitor
participation and contain expenditure if the response is
higher than anticipated.
The study ID and no other information will be used for
the randomisation. The nature of the intervention and the
randomization ratio precludes masking of participants
and other study staff, including the data analyst.Data plan
Data collection
There are a number of ways in which participant infor-
mation will be returned and collected. Women can
post back their pathology information form, call the
telephone centre and update details, or return the com-
pleted kit (with the form), or staff at VCCR process the re-
turn to sender generated during mailout. The data flow will
go through several checkpoints of information matching
and validation prior to entry, amendment of details or sam-
ple processing. Additionally, women in the self-sampling
arm will return the questionnaire by post. These question-
naires will be anonymous, therefore when they are returned
they cannot be linked to a specific woman.
Data analysis
Within each stratum (never- and under-screened) the pro-
portion of women in each arm participating (i.e. primary
outcome) will be calculated as will the absolute difference
in the proportion of participation between the HPV self-
sampling and current practice arms and the correspond-
ing 95% confidence interval and two-sided p-value. An
intention-to-treat approach will be used for the analysis,
with women who subsequently report they are adequately
screened, are pregnant, or have had a hysterectomy, or re-
turn to sender, analysed within the arm to which they were
randomised. We will also calculate adjusted participation
proportions, in which women who report that they are
pregnant, have had a hysterectomy, or that they are ad-
equately screened, or return to sender, are removed from
the denominators. Participation will be also be reported by
age, socio-economic status (SES), cultural background,
Indigenous status and time since last Pap test (for under-
screened only) within each screening group and trial arm
status. SES status classification is an area level variable
assigned to women according to their postcode of residence
based on the ABS Index of Relative Socioeconomic Disad-
vantage (ABS 2008) which is derived from Census informa-
tion. Additionally, the distribution of age and SES will be
compared between women who participate and those who
don’t within each screening group and trial arm. Estimates
and 95% confidence intervals of the proportion of women
having appropriate further investigation (i.e. secondary
outcome) in the overall and sub-groups of positive HPV
test for each screening group will also be calculated. The re-
sponses to the different items (i.e. items within the themes:
psycho-social, feasibility and practical issues) of the self-
sampling follow-up questionnaire will be summarised and
reported as the total number and proportion. We will also
report the reasons for not returning a self-sampling kit.
Data security
VCCR has strict data security arrangements, data privacy
and data linkage policies and protocols in place to ensure
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that it holds. Additional conditions surround the VEC data
which include all staff involved signing confidentiality
agreements, to ensure that the information remains confi-
dential and protected. The information provided by the
VEC has been allowed based on the public health benefit
of this research and will not be used for any other pur-
poses. The collating of the letters and/or letters and kits
and inserting into envelopes is performed in a specifically
designed and purpose built area with limited staff access.
In accordance with VEC requirements, VCCR will fully
destroy the information collected from VEC at three months
from the date of release of the electoral roll from VEC,
except for women selected for the study. The details of
women selected for the study who do not participate
will be deleted after 12 months. Year of birth and post-
code will however be retained for statistical purposes.
Notably when a never-screened woman returns the kit
and consents to her information being recorded on the
VCCR this information is no longer VEC data and be-
comes VCCR data. The final data set for analysis will
be de-identified and published in an aggregate manner
so confidentiality will be protected.
Ethics
The study was approved by the Human Research Ethics
Committee (HREC) of the Victorian Department of Health.
Informed consent has been waived for the study because it
is primarily a trial of participation in screening, and we wish
the results to be directly translatable to the current screen-
ing program. Asking women to consent to a trial of partici-
pation would potentially invalidate such results. However,
women are otherwise fully informed about the testing and
subsequent follow-up and once a woman returns the kit
with a pathology information form it will represent her
consent to test her sample and undergo further appropri-
ate management and use of data. Correspondence sent to
women includes a clear statement indicating the process
under which VCCR obtained addresses from the electoral
roll and participant information form includes statements
about privacy of information. Additional information on
how the data collected will be stored and utilized in the
study is detailed in the brochure sent with the kit or the
reminder letter. Provision has been offered for women to
opt-off the study. VCCR will inform VEC of women who
opt-off and who do not want to be contacted for health
screening purposes in future. All materials were revised
following focus groups and amended materials submitted
for consideration by HREC.
A Data Safety Monitoring Board (DSMB) has been
appointed for the duration of the study. The DSMB will
be responsible for the review of the primary outcome data.
The DSMB will be provided with the full outcome data at
six and twelve months post mail-out of the invitation letter.Following review of the data, the DSMB will report back
to the Principal investigator with written details of any
identified issues and/or recommendations. An interim
analysis will also be performed on the primary end point
when 50% of the mail-outs have occurred (anticipated to
take place around the 3rd month post initial contact). The
DSMB could halt or extend the study based on the pri-
mary end points. They will also provide clinical advice on
detected high-risk HPV where a woman is non-compliant
with follow-up, and assess VCCR compliance of follow-up
reminders based on participants becoming part of the
routine screening program.
Discussion
The success of the National Cervical Screening Program
is limited by incomplete and unrepresentative participation.
More than half of invasive cervical cancers presently occur
in women who have never been screened and close to a
quarter occur in women who are under-screened. Improv-
ing participation and reducing inequalities are important
priorities for the cervical screening program and new
strategies are needed to target the hardest to reach
women. HPV self-sampling is a valid screening test that
performs better than cervical cytology in detecting abnor-
malities and has the potential to overcome known barriers
to screening, as trials have shown it can improve partici-
pation by hard-to-reach groups, although the participation
rates varied widely between countries. Given the im-
portance of the local context to screening participation,
evidence from Australian trials is necessary to inform
policy. None of the previous published trials have had suf-
ficient power to evaluate participation of never-screened
women separate to under-screened. This novel aspect of
the study has great public health significance as these
women are hardest to reach and have the highest rate of
cervical cancer. A pragmatic trial of HPV self-sampling is
timely and the findings will have direct relevance to the
cervical screening program.
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